Market
Story
FDA Approves Eli Lilly's Zepbound as First and Only Treatment for Sleep Apnea, Reducing Breathing Interruptions by 25
Dec 20, 2024, 09:55 PM
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly's Zepbound (tirzepatide) as the first and only prescription medication for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. This approval, announced on December 20, 2024, allows Zepbound to be used in conjunction with a reduced-calorie diet and increased physical activity. Clinical data indicates that adults using Zepbound experienced at least 25 fewer breathing interruptions per hour, with up to 50% of patients reporting no symptoms after one year of treatment. The approval may also facilitate broader insurance coverage for the medication, which is primarily recognized for its weight-loss benefits.
View original story
Similar markets
40% to 50% • 25%
More than 60% • 25%
50% to 60% • 25%
Less than 40% • 25%
0-25% reduction • 25%
26-50% reduction • 25%
76-100% reduction • 25%
51-75% reduction • 25%
1 million to 2 million • 25%
More than 2 million • 25%
500,000 to 1 million • 25%
Less than 500,000 • 25%
70% to 80% • 25%
60% to 70% • 25%
Less than 60% • 25%
More than 80% • 25%
Less than 100,000 • 25%
More than 300,000 • 25%
200,000 to 300,000 • 25%
100,000 to 200,000 • 25%
20% to 25% • 25%
15% to 20% • 25%
Less than 15% • 25%
More than 25% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
11 to 15 • 25%
5 to 10 • 25%
Less than 5 • 25%
More than 15 • 25%